TABLE OF CONTENTS. Volume 4 Number 7 September V. Broshtilova, M. Balabanova S. Huang, Y. H. Zhang.1145

Size: px
Start display at page:

Download "TABLE OF CONTENTS. Volume 4 Number 7 September V. Broshtilova, M. Balabanova S. Huang, Y. H. Zhang.1145"

Transcription

1

2

3 Journal of Cancer Therapy, 2013, 4, Published Online September 2013 in SciRes ( TABLE OF CONTENTS Volume 4 Number 7 September 2013 Cross Skin Reactivity to Tyrosine Kinase Inhibitors in a Patient with Chronic Myelogenous Leukemia V. Broshtilova, M. Balabanova A Case Report of Fever of Unknown Origin (FUO) S. Huang, Y. H. Zhang.1145 Prolonged Radiographic Stabilization of a Metastatic Octreotide Scan-Positive Poorly Differentiated Neuroendocrine Tumor Using Octreotide Acetate Therapy Alone S. Sorscher 1148 Persimmon Leaf Flavonols Enhance the Anti-Cancer Effect of Heavy Ion Radiotherapy on Murine Xenograft Tumors K. Kawakami, H. Nishida, N. Tatewaki, K. Eguchi-Kasai, K. Anzai, T. Eitsuka, T. Konishi., M. Hirayama Primary Melanoma of the Vagina Treated by Imatinib: Case Report K. Oualla, F. El mrabet, H. Elfatemi, S. Arifi, N. Mellas, A. Banani, S. Tizniti, A. Amarti, O. Elmesbahi 1158 Circulating Tumor Cell Cultures as a Predictive Marker during Salvage Therapy of Refractory Merkel Cell Carcinoma with Chemotherapy and Electron Beam Radiation S. Donepudi, S. A. Reisinger, J. R. McGregor, S. Tharkar, S. Samlowski, D. Ostler, S. Shen, W. E. Samlowski 1162 The Role of Everolimus in the Treatment of Breast Cancer J. P. Leone, R. H. Álvarez 1167 The Aryl Hydrocarbon Receptor: A Target for Breast Cancer Therapy J. B. Powell, G. D. Goode, S. E. Eltom 1177 The MMTV-PyVT Transgenic Mouse as a Multistage Model for Mammary Carcinoma and the Efficacy of Antineoplastic Treatment S. Shishido, A. Delahaye, A. Beck, T. A. Nguyen 1187 Work Productivity and Activity Impairment in Colorectal Cancer Patients Treated with Capecitabine G. Malaguarnera, M. Pennisi, G. Grosso, M. Vacante, S. Salomone, F. Drago, M. Malaguarnera, E. Ozyalcin, M. Motta, V. Raciti, M. Malaguarnera Ductal Carcinoma in Situ Treatment Requires a Multidisciplinary Approach C. Constantinou, I. S. Fentiman Treatment in Elderly Glioblastoma Patients: General Reduction of Standard Therapy Should Be Avoided. Prognostic Value of MGMT Is Questionable J. Pichler, I. Hoellmüller, B. Ghanim, S. Spiegl-Kreinecker 1217 Copyright 2013 SciRes. JCT

4 Journal of Cancer Therapy, 2013, 4, Published Online September 2013 in SciRes ( Work Productivity and Activity Impairment in Breast Cancer Patients Treated with Capecitabine M. Vacante, G. Malaguarnera, M. Pennisi, G. Grosso, S. Salomone, F. Drago, E. Ozyalcin, V. Catania, A. Consoli, M. Malaguarnera Sphincter Saving Surgeries for Locally Advanced Low Rectal Cancer after Neoadjuvant Chemoradiation M. A. E. Salem, H. A. Hamza, G. Amira, A. E. Ibrahium, A. A. S. Salem 1228 Combination Therapy of Capecitabine with Cyclophosphamide as a Second-Line Treatment after Failure of Paclitaxel plus Bevacizumab Treatment in a Human Triple Negative Breast Cancer Xenograft Model M. Yanagisawa, K. Yorozu, M. Kurasawa, Y. Moriya, N. Harada Maintenance Chemotherapy in Ovarian Cancer: A Trial-Sequential Analysis A. Messori, V. Fadda, D. Maratea, S. Trippoli 1242 Annonaa muricata Linn Leaf Induce Apoptosis in Cancer Cause Virus O. P. Astirin, A. N. Artanti, M. S. Fitria, E. A. Perwitasari, A. Prayitno 1244 Clinical and Dosimetric Implications of Air Gaps between Bolus and Skin Surface during Radiation Therapy Y. Khan, J. E. Villarreal-Barajas, M. Udowicz, R. Sinha, W. Muhammad, A. N. Abbasi, A. Hussain 1251 Quality of Life in Egyptian Children with Cancer M. Fawzy, M. Saleh, M. El-Wakil, Z. Monir, E. Eltahlawy Controlled Local Hyperthermia and Magnetic Hyperthermia of Surface (Skin) Cancer Diseases Z. Kovziridze, P. Khorava, N. Mitskevich The figure on the front cover is from the article published in Journal of Cancer Therapy, 2013, Vol. 4, No. 7, pp by José Pablo Leone and Ricardo H. Álvarez. Copyright 2013 SciRes. JCT

5 Journal of Cancer Therapy (JCT) Journal Information SUBSCRIPTIONS The Journal of Cancer Therapy (Online at Scientific Research Publishing, is published monthly by Scientific Research Publishing, Inc., USA. Subscription rates: Print: $59 per issue. To subscribe, please contact Journals Subscriptions Department, SERVICES Advertisements Advertisement Sales Department, Reprints (minimum quantity 100 copies) Reprints Co-ordinator, Scientific Research Publishing, Inc., USA. COPYRIGHT Copyright 2013 Scientific Research Publishing, Inc. All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except as described below, without the permission in writing of the Publisher. Copying of articles is not permitted except for personal and internal use, to the extent permitted by national copyright law, or under the terms of a license issued by the national Reproduction Rights Organization. Requests for permission for other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale, and other enquiries should be addressed to the Publisher. Statements and opinions expressed in the articles and communications are those of the individual contributors and not the statements and opinion of Scientific Research Publishing, Inc. We assumes no responsibility or liability for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained herein. We expressly disclaim any implied warranties of merchantability or fitness for a particular purpose. If expert assistance is required, the services of a competent professional person should be sought. PRODUCTION INFORMATION For manuscripts that have been accepted for publication, please contact: jct@scirp.org

6

ISSN: Vol. 1, No. 1, August 2012

ISSN: Vol. 1, No. 1, August 2012 Vol. 1, No. 1, August 2012 9 772169 965001 01 ISSN 2169-9658 (Print) ISSN 2169-9674 (Online) Editorial Board Prof. Massimo Cocchi Dr. Emily Piven Haltiwanger Dr. Ivandro Soares Monteiro Dr. Minati Singh

More information

TABLE OF CONTENTS. Volume 1 Number 5 December P. Saariluoma1, A. Oulasvirta 317. F. Bonoti, P. Metallidou 329

TABLE OF CONTENTS. Volume 1 Number 5 December P. Saariluoma1, A. Oulasvirta 317. F. Bonoti, P. Metallidou 329 Psychology, 2010, 1, 317-393 Published Online December 2010 in SciRes (http://www.scirp.org/journal/psych/) TABLE OF CONTENTS Volume 1 Number 5 December 2010 User Psychology: Re-assessing the Boundaries

More information

TABLE OF CONTENTS. Volume 2 Number 4 October Symptom Cluster Research in Women with Breast Cancer: A Comparison of Three Subgrouping Techniques

TABLE OF CONTENTS. Volume 2 Number 4 October Symptom Cluster Research in Women with Breast Cancer: A Comparison of Three Subgrouping Techniques Advances in Breast Cancer Research, 2013, 2, 107-169 Published Online October 2013 in SciRes (http://www.scirp.org/journal/abcr/) TABLE OF CONTENTS Volume 2 Number 4 October 2013 Symptom Cluster Research

More information

TABLE OF CONTENTS. Volume 2, Number 11, November 2010

TABLE OF CONTENTS. Volume 2, Number 11, November 2010 Vol.2, No.11, 1181-1325 (2010) NS TABLE OF CONTENTS Volume 2, Number 11, November 2010 ASTRONOMY Is it plausible to expect a close encounter of the Earth with a yet undiscovered astronomical object in

More information

Food and Nutrition Sciences, 2011, 2, Published Online October 2011 in SciRes ( TABLE OF CONTENTS

Food and Nutrition Sciences, 2011, 2, Published Online October 2011 in SciRes (  TABLE OF CONTENTS 9 772157 944001 08 Food and Nutrition Sciences, 2011, 2, 793-907 Published Online October 2011 in SciRes (http://www.scirp.org/journal/fns/) TABLE OF CONTENTS Volume 2 Number 8 October 2011 Determination

More information

TABLE OF CONTENTS. Volume 3 Number 4 December 2013

TABLE OF CONTENTS. Volume 3 Number 4 December 2013 Advances in Infectious Diseases, 2013, 3, 231-305 Published Online December 2013 in SciRes (http://www.scirp.org/journal/aid/) TABLE OF CONTENTS Volume 3 Number 4 December 2013 Development of New Strategy

More information

TABLE OF CONTENTS. Volume 3 Number 4 November 2013

TABLE OF CONTENTS. Volume 3 Number 4 November 2013 Open Journal of Rheumatology and Autoimmune Diseases, 2013, 3, 181-269 Published Online November 2013 in SciRes (http://www.scirp.org/journal/ojra/) TABLE OF CONTENTS Volume 3 Number 4 November 2013 Evaluation

More information

Vol.3, No.5, (2013) TABLE OF CONTENTS. Volume 3, Number 5, October 2013

Vol.3, No.5, (2013) TABLE OF CONTENTS. Volume 3, Number 5, October 2013 Vol.3, No.5, 419-520 (2013) ABC TABLE OF CONTENTS Volume 3, Number 5, October 2013 Serum lipid growth curves for children and adolescents in predicting adult dyslipidemia (data from the Slovak Lipid Community

More information

TABLE OF CONTENTS. Volume 3 Number 10 October Influence of Traditional Inoculum and Fermentation Time on the Organoleptic Quality of Attiéké

TABLE OF CONTENTS. Volume 3 Number 10 October Influence of Traditional Inoculum and Fermentation Time on the Organoleptic Quality of Attiéké 9 772157 944001 1 0 Food and Nutrition Sciences, 2012, 3, 1335-1471 Published Online October 2012 in SciRes (http://www.scirp.org/journal/fns/) TABLE OF CONTENTS Volume 3 Number 10 October 2012 Influence

More information

TABLE OF CONTENTS. Volume 4 Number 12 December 2013

TABLE OF CONTENTS. Volume 4 Number 12 December 2013 Food and Nutrition Sciences, 2013, 4, 1191-1306 Published Online December 2013 in SciRes (http://www.scirp.org/journal/fns/) TABLE OF CONTENTS Volume 4 Number 12 December 2013 Effects of Pressurized Argon

More information

Vol.2, No.1, 1-88 (2012) TABLE OF CONTENTS. Volume 2, Number 1, March 2012

Vol.2, No.1, 1-88 (2012) TABLE OF CONTENTS. Volume 2, Number 1, March 2012 9 772160 879000 01 Vol.2, No.1, 1-88 (2012) OJOG TABLE OF CONTENTS Volume 2, Number 1, March 2012 Metformin: A possible drug for treatment of endometrial cancer K. Tsuji, I. Kisu, K. Banno, M. Yanokura,

More information

TABLE OF CONTENTS. Volume 2 Number 6 August 2011

TABLE OF CONTENTS. Volume 2 Number 6 August 2011 9 772157 944001 06 Food and Nutrition Sciences, 2011, 2, 511-683 Published Online August 2011 in SciRes (http://www.scirp.org/journal/fns/) TABLE OF CONTENTS Volume 2 Number 6 August 2011 Nutritional

More information

Table of Contents. Volume 7 Number 2 May 2018

Table of Contents. Volume 7 Number 2 May 2018 9 772168 543002 02 International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 2018, 7, 131-272 http://www.scirp.org/journal/ijmpcero ISSN Online: 2168-5444 ISSN Print: 2168-5436

More information

TABLE OF CONTENTS. Volume 4 Number 9 September R. Kumar, T. Kathiravan, R. Rajamanickam, S. Nadanasabapathi 873

TABLE OF CONTENTS. Volume 4 Number 9 September R. Kumar, T. Kathiravan, R. Rajamanickam, S. Nadanasabapathi 873 Food and Nutrition Sciences, 2013, 4, 873-997 Published Online September 2013 in SciRes (http://www.scirp.org/journal/fns/) TABLE OF CONTENTS Volume 4 Number 9 September 2013 Institutional Foods Development

More information

TABLE OF CONTENTS. Volume 4 Number 7A July 2013

TABLE OF CONTENTS. Volume 4 Number 7A July 2013 Food and Nutrition Sciences, 2013, 4, 1-130 Published Online July 2013 in SciRes (http://www.scirp.org/journal/fns/) TABLE OF CONTENTS Volume 4 Number 7A July 2013 Quantification of Antibiotic Residues

More information

TABLE OF CONTENTS. Volume 4 Number 3 March 2013

TABLE OF CONTENTS. Volume 4 Number 3 March 2013 Food and Nutrition Sciences, 2013, 4, 233-356 Published Online March 2013 in SciRes (http://www.scirp.org/journal/fns/) TABLE OF CONTENTS Volume 4 Number 3 March 2013 Etiology of Diarrhea among Severely

More information

Table of Contents. Volume 4 Number 13 September 2014

Table of Contents. Volume 4 Number 13 September 2014 Open Journal of Obstetrics and Gynecology, 2014, 4, 733-808 Published Online September 2014 in SciRes. http://www.scirp.org/journal/ojog Table of Contents Volume 4 Number 13 September 2014 Case Series

More information

Table of Contents. Volume 4 Number 6 April Effect of Carbohydrate Intolerance and Gestational Diabetes on Obstetric and Perinatal Outcomes

Table of Contents. Volume 4 Number 6 April Effect of Carbohydrate Intolerance and Gestational Diabetes on Obstetric and Perinatal Outcomes Open Journal of Obstetrics and Gynecology, 2014, 4, 243-341 Published Online April 2014 in SciRes. http://www.scirp.org/journal/ojog Table of Contents Volume 4 Number 6 April 2014 Effect of Carbohydrate

More information

Table of Contents. Volume 6 Number 4 November Method for Converting Cone-Beam CT Values into Hounsfield Units for Radiation Treatment Planning

Table of Contents. Volume 6 Number 4 November Method for Converting Cone-Beam CT Values into Hounsfield Units for Radiation Treatment Planning 9 772168 543002 04 International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 2017, 6, 361-467 http://www.scirp.org/journal/ijmpcero ISSN Online: 2168-5444 ISSN Print: 2168-5436

More information

TABLE OF CONTENTS. Synergistic Anti-Tumor Effect of Cisplatin When Combined with an Anti-Src Kinase Integrin-Based Peptide

TABLE OF CONTENTS. Synergistic Anti-Tumor Effect of Cisplatin When Combined with an Anti-Src Kinase Integrin-Based Peptide 9 772151 193009 03 Journal of Cancer Therapy, 2011, 2, 295-440 Published Online August 2011 in SciRes (http://www.scirp.org/journal/jct/) TABLE OF CONTENTS Volume 2 Number 3 August 2011 Synergistic Anti-Tumor

More information

TABLE OF CONTENTS. Volume 4 Number 1 February 2014

TABLE OF CONTENTS. Volume 4 Number 1 February 2014 Open Journal of Rheumatology and Autoimmune Diseases, 2014, 4, 1-73 Published Online February 2014 in SciRes (http://www.scirp.org/journal/ojra/) TABLE OF CONTENTS Volume 4 Number 1 February 2014 Two Approaches

More information

Table of Contents. Volume 4 Number 4 August Involvement of Serotonergic System and Magnesium on Anxiolytic Effects of Pomegranate in Male Mice

Table of Contents. Volume 4 Number 4 August Involvement of Serotonergic System and Magnesium on Anxiolytic Effects of Pomegranate in Male Mice World Journal of Neuroscience, 2014, 4, 293-393 Published Online August 2014 in SciRes. http://www.scirp.org/journal/wjns Table of Contents Volume 4 Number 4 August 2014 Involvement of Serotonergic System

More information

Table of Contents. Volume 6 Number 13 December S. Byford, E. Weaver A. Oraif

Table of Contents. Volume 6 Number 13 December S. Byford, E. Weaver A. Oraif 9 772160 879000 1 3 Open Journal of Obstetrics and Gynecology, 2016, 6, 785-887 http://www.scirp.org/journal/ojog ISSN Online: 2160-8806 ISSN Print: 2160-8792 Table of Contents Volume 6 Number 13 December

More information

Table of Contents. Volume 6 Number 11 August Dietary Calcium Intake and Associated Factors among Pregnant Women in Southern Benin in 2014

Table of Contents. Volume 6 Number 11 August Dietary Calcium Intake and Associated Factors among Pregnant Women in Southern Benin in 2014 Food and Nutrition Sciences, 2015, 6, 945-1070 Published Online August 2015 in SciRes. http://www.scirp.org/journal/fns Table of Contents Volume 6 Number 11 August 2015 Dietary Calcium Intake and Associated

More information

Table of Contents. Volume 7 Number 12 November 2017

Table of Contents. Volume 7 Number 12 November 2017 9 772160 879000 12 Open Journal of Obstetrics and Gynecology, 2017, 7, 1151-1238 http://www.scirp.org/journal/ojog ISSN Online: 2160-8806 ISSN Print: 2160-8792 Table of Contents Volume 7 Number 12 November

More information

Vol.3, No.3, (2013) TABLE OF CONTENTS. Volume 3, Number 3, September F. Y. Jiao, X. P. Yan 177

Vol.3, No.3, (2013) TABLE OF CONTENTS. Volume 3, Number 3, September F. Y. Jiao, X. P. Yan 177 Vol.3, No.3, 177-289 (2013) OJPed TABLE OF CONTENTS Volume 3, Number 3, September 2013 A special and rare case with osteomyelitis: A case report F. Y. Jiao, X. P. Yan 177 Lead poisoning due to appendiceal

More information

TABLE OF CONTENTS. Volume 5 Number 2 January 2014

TABLE OF CONTENTS. Volume 5 Number 2 January 2014 Food and Nutrition Sciences, 2014, 5, 97-244 Published Online January 2014 in SciRes (http://www.scirp.org/journal/fns/) TABLE OF CONTENTS Volume 5 Number 2 January 2014 Antioxidant and Antimicrobial Activities

More information

TABLE OF CONTENTS. Volume 3 Number 6 December Genetic Background May Confer Susceptibility to PTC in Benign Multinodular Thyroid Disease

TABLE OF CONTENTS. Volume 3 Number 6 December Genetic Background May Confer Susceptibility to PTC in Benign Multinodular Thyroid Disease 9 772151 193009 06 Journal of Cancer Therapy, 2012, 3, 997-1203 Published Online December 2012 in SciRes (http://www.scirp.org/journal/jct/) TABLE OF CONTENTS Volume 3 Number 6 December 2012 Genetic Background

More information

Clinical Policy: Pertuzumab (Perjeta) Reference Number: ERX.SPMN.94

Clinical Policy: Pertuzumab (Perjeta) Reference Number: ERX.SPMN.94 Clinical Policy: (Perjeta) Reference Number: ERX.SPMN.94 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type. Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic

More information

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on

More information

Clinical Policy: Regorafenib (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12/12 Last Review Date: 11/16

Clinical Policy: Regorafenib (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12/12 Last Review Date: 11/16 Clinical Policy: (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12/12 Last Review Date: 11/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Clinical Policy: Cetuximab (Erbitux) Reference Number: ERX.SPA.261 Effective Date:

Clinical Policy: Cetuximab (Erbitux) Reference Number: ERX.SPA.261 Effective Date: Clinical Policy: (Erbitux) Reference Number: ERX.SPA.261 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

The Clinical Research E-News

The Clinical Research E-News Volume 4: ISSUE 6: August 28, 2012 The Clinical Research E-News Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Trials Opened at

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Imfinzi) Reference Number: CP.PHAR.339 Effective Date: 07.01.17 Last Review Date: 05.18 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important

More information

Copyright 2017 by Rochelle Barlow, ASLDoneRight, ASL Rochelle. All rights reserved.

Copyright 2017 by Rochelle Barlow, ASLDoneRight, ASL Rochelle. All rights reserved. Copyright 2017 by Rochelle Barlow, ASLDoneRight, ASL Rochelle. All rights reserved. You are welcome to print a copy of this document for your personal use. Other than that, no part of this publication

More information

Summary of Research and Writing Activities in Oncology

Summary of Research and Writing Activities in Oncology Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,

More information

REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - Executive Summary The table below presents the key metrics for Kadcyla for human epidermal growth factor

More information

National Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007

National Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007 Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Lynparza) Reference Number: CP.PHAR.360 Effective Date: 10.03.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical

More information

CURRICULUM VITAE PERSONAL DETAILS: RAHAL, MOHAMED

CURRICULUM VITAE PERSONAL DETAILS: RAHAL, MOHAMED PERSONAL DETAILS: CURRICULUM VITAE NAME: RAHAL, MOHAMED MARITAL STATUS: ADDRESS: Married, 3 children King Fahad Specialist Hospital Oncology Department PO BOX 14563 DAMMAM 31434 Kingdom of Saudi Arabia

More information

It is a malignancy originating from breast tissue

It is a malignancy originating from breast tissue 59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast

More information

Workout of the Day. For More Plyometric Workouts, Please Visit:

Workout of the Day. For More Plyometric Workouts, Please Visit: Workout of the Day For More Plyometric Workouts, Please Visit: http://americancoachingacademy.com/plyometrics/ IT IS ILLEGAL TO POST THIS DOCUMENT ONLINE The material enclosed is copyrighted. You do not

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.HNMC.09 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.HNMC.09 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC Clinical Policy: (Cyramza) Reference Number: CP.HNMC.09 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy

More information

Synribo (Chronic Myeloid Leukemia)

Synribo (Chronic Myeloid Leukemia) Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 GDHC1141DFR / Published May 2013 Executive Summary Synribo (omacetaxine mepesuccinate): Key Metrics in CML Markets 2012 Synribo Sales

More information

Studienverzeichnis Medizinische Onkologie

Studienverzeichnis Medizinische Onkologie Studienverzeichnis Medizinische Onkologie Mammakarzinom, Gynäkologie 21/12 24/14 25/14 96/12 PALLAS I I Transdermal CR1447 (4-OH-testosterone) in endocrine responsive-her2 negative and triple negative-androgen

More information

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019 MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments

More information

NHS. High dose rate brachytherapy for carcinoma of the cervix. National Institute for Health and Clinical Excellence. Issue date: March 2006

NHS. High dose rate brachytherapy for carcinoma of the cervix. National Institute for Health and Clinical Excellence. Issue date: March 2006 NHS National Institute for Health and Clinical Excellence Issue date: March 2006 High dose rate brachytherapy for carcinoma of Understanding NICE guidance information for people considering the procedure,

More information

Responsible Alcohol Service for Lafourche Parish

Responsible Alcohol Service for Lafourche Parish Server Responsibility As a Server of alcohol in the state of Louisiana, it is your responsibility to adhere to the local ordinance governing the sale and service of alcohol and tobacco. Ordinances may

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Erbitux) Reference Number: CP.PHAR.317 Effective Date: 02.01.17 Last Review Date: 11.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder

More information

Avastin (bevacizumab)

Avastin (bevacizumab) Avastin (bevacizumab) Policy Number: 5.02.502 Last Review: 04/2018 Origination: 03/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Avastin

More information

Clinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17

Clinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17 Clinical Policy: (Tykerb) Reference Number: CP.PHAR.79 Effective Date: 10.01.11 Last Review Date: 11.17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Temozolomide (Temodar) Reference Number: ERX.SPA.138 Effective Date:

Clinical Policy: Temozolomide (Temodar) Reference Number: ERX.SPA.138 Effective Date: Clinical Policy: (Temodar) Reference Number: ERX.SPA.138 Effective Date: 03.01.14 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Posters and Presentations

Posters and Presentations Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

Imaging Cancer Treatment Complications in the Chest

Imaging Cancer Treatment Complications in the Chest Imaging Cancer Treatment Complications in the Chest Michelle S. Ginsberg, MD Objectives Imaging Cancer Treatment Complications in the Chest To understand the mechanisms of action of different classes of

More information

Molecular Imaging in the Development of Cancer Therapeutics. Johannes Czernin

Molecular Imaging in the Development of Cancer Therapeutics. Johannes Czernin Molecular Imaging in the Development of Cancer Therapeutics Johannes Czernin Ahmanson Biological Imaging Division University of California Los Angeles Cancer Statistics Cancer Type 5-year Survival Rate

More information

CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2 neu-positive breast cancer

CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2 neu-positive breast cancer CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2 neu-positive breast cancer The Harvard community has made this article openly available. Please share how this

More information

National Cancer Drugs Fund List - Approved

National Cancer Drugs Fund List - Approved National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer

More information

Conquering Carpal Tunnel Syndrome

Conquering Carpal Tunnel Syndrome Conquering Carpal Tunnel Syndrome PainReliefSciences.com 1 Copyright 2016 NutriFrontier Limited All rights reserved Published by Kevin Richardson. No part of this publication may be reproduced, stored

More information

Colorectal Cancer Dashboard

Colorectal Cancer Dashboard Process Risk Assessment Presence or absence of cancer in first-degree blood relatives documented for patients with colorectal cancer Percent of patients with colorectal cancer for whom presence or absence

More information

Table of Contents. Volume 6 Number 11 May Do Functional Problems and Neighborhood Disturbances in and around the Home Trigger Injuries?

Table of Contents. Volume 6 Number 11 May Do Functional Problems and Neighborhood Disturbances in and around the Home Trigger Injuries? Health, 2014, 6, 1085-1332 Published Online May 2014 in SciRes. http://www.scirp.org/journal/health Table of Contents Volume 6 Number 11 May 2014 Do Functional Problems and Neighborhood Disturbances in

More information

REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Stivarga for colorectal cancer (CRC) in the eight major

More information

REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Vectibix for colorectal cancer (CRC) in the eight major

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated

More information

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.PHAR.119

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.PHAR.119 Clinical Policy: (Cyramza) Reference Number: CP.PHAR.119 Effective Date: 05/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Treatment of gastrointestinal cancer. General considerations International guidelines

Treatment of gastrointestinal cancer. General considerations International guidelines Treatment of gastrointestinal cancer General considerations International guidelines Therapeutical options Chemotherapy Moleculary targeted therapy Irradiation Immunotherapy Radiological intervention Oncosurgery

More information

ENETS Consensus Guidelines for the Standard of Care in

ENETS Consensus Guidelines for the Standard of Care in Neuroendocrinology (DOI:10.1159/000457957) (Accepted, unedited article not yet assigned to an issue) Advanced Release: February 11, 2017 2017 S. Karger AG, Basel www.karger.com/nen Received: December 12,

More information

COLORECTAL CANCER 44

COLORECTAL CANCER 44 COLORECTAL CANCER 44 Colorectal Cancer Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Stuart M. Lichtman, MD Memorial Sloan-Kettering Cancer Center Commack,

More information

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS QOPI5 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Percentage of adult patients with metastatic solid tumors

More information

Targeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009

Targeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Targeted Medicine and Molecular Therapeutics Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Approaches to Cancer Prevention Screening and early diagnosis

More information

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A Local Coverage Determination (LCD): Circulating Tumor Cell Marker Assays (L35096) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information

More information

Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia (CML) Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is

More information

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015 Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib

More information

Open Journal of Stomatology

Open Journal of Stomatology Volume 7, Number 9, September 2017 Scientific Research Publishing Open Journal of Stomatology www.scirp.org/journal/ojst 9 772160 870007 09 ISSN 2160-8709 (Print) ISSN 2160-8717 (Online) Editor-in-Chief

More information

Responsible Alcohol Service for Jefferson Davis Parish

Responsible Alcohol Service for Jefferson Davis Parish Server Responsibility As a Server of alcohol in the state of Louisiana, it is your responsibility to adhere to the local ordinance governing the sale and service of alcohol and tobacco. Ordinances may

More information

Denominator Criteria (Eligible Cases): Patient encounter during the performance period (CPT): 78300, 78305, 78306, 78315, 78320

Denominator Criteria (Eligible Cases): Patient encounter during the performance period (CPT): 78300, 78305, 78306, 78315, 78320 Quality ID #147: Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.

More information

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President

More information

CADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness

CADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness CADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness Service Line: Rapid Response Service Version: 1.0 Publication Date: August

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of

More information

STATE OF THE ART 4: Combination Immune Therapy-Chemotherapy. Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI)

STATE OF THE ART 4: Combination Immune Therapy-Chemotherapy. Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI) STATE OF THE ART 4: Combination Immune Therapy-Chemotherapy Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI) Topics for Consideration What are the rules for integrating

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Stivarga) Reference Number: CP.CPA.157 Effective Date: 11.16.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

CLINICAL TRIALS ACC. Jul 2016

CLINICAL TRIALS ACC. Jul 2016 CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and

More information

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles 2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla

More information

Responsible Alcohol Service for Ascension Parish

Responsible Alcohol Service for Ascension Parish Server Responsibility As a Server of alcohol in the state of Louisiana, it is your responsibility to adhere to the local ordinance governing the sale and service of alcohol and tobacco. Ordinances may

More information

Cancer Metronomic Therapy Milan, February 26, 2016

Cancer Metronomic Therapy Milan, February 26, 2016 Cancer Metronomic Therapy Milan, February 26, 2016 Metronomic Chemotherapy: Evolution and Development of the Concept Robert S. Kerbel, PhD Senior Scientist Sunnybrook Research Institute Professor, Dept.

More information

Clinical Policy: Pertuzumab (Perjeta) Reference Number: CP.PHAR.227 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Pertuzumab (Perjeta) Reference Number: CP.PHAR.227 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Perjeta) Reference Number: CP.PHAR.227 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the

More information

Responsible Alcohol Service for St. Martin Parish

Responsible Alcohol Service for St. Martin Parish Server Responsibility As a Server of alcohol in the state of Louisiana, it is your responsibility to adhere to the local ordinance governing the sale and service of alcohol and tobacco. Ordinances may

More information

Breast Cancer Diagnosis, Treatment and Follow-up

Breast Cancer Diagnosis, Treatment and Follow-up Breast Cancer Diagnosis, Treatment and Follow-up What is breast cancer? Each of the body s organs, including the breast, is made up of many types of cells. Normally, healthy cells grow and divide to produce

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/

More information

Adjuvant Chemotherapy for Rectal Cancer: Are we making progress?

Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones

More information

Sami Shousha Editor. Breast Pathology. Problematic Issues

Sami Shousha Editor. Breast Pathology. Problematic Issues Breast Pathology Editor Breast Pathology Problematic Issues Editor Charing Cross Hospital Imperial College Healthcare NHS Trust & Imperial College London United Kingdom ISBN 978-3-319-28653-2 ISBN 978-3-319-28655-6

More information